For instance, patient treated with BCMA-targeted CAR-T cells, BCMA expression on MM cells was decreased significantly [49], which raises the need to create BTCEs with the ability to target multiple tumor antigens simultaneously to circumvent antigen-less tumor escape and patient relapse. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.